XML 36 R25.htm IDEA: XBRL DOCUMENT v3.25.2
Collaborative Arrangements (Tables)
 6 Months Ended
Jun. 30, 2025
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2025202420252024
Alliance revenue - Lynparza$370 $317 $682 $609 
Alliance revenue - Koselugo43 37 87 75 
Total alliance revenue$413 $354 $769 $684 
Cost of sales (1)
86 82 169 163 
Selling, general and administrative40 43 72 82 
Research and development16 18 28 38 
($ in millions)June 30, 2025December 31, 2024
Receivables from AstraZeneca included in Other current assets
$411 $424 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
12 713 
(1)    Represents amortization of capitalized milestone payments.
(2)    Balance at December 31, 2024 includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2025202420252024
Alliance revenue - Lenvima$265 $249 $523 $504 
Cost of sales (1)
60 60 121 121 
Selling, general and administrative35 41 66 80 
Research and development3 6 7 13 
($ in millions)June 30, 2025December 31, 2024
Receivables from Eisai included in Other current assets
$265 $257 
(1)    Represents amortization of capitalized milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2025202420252024
Alliance revenue - Adempas/Verquvo$123 $106 $229 $203 
Net sales of Adempas recorded by Merck80 72 147 142 
Net sales of Verquvo recorded by Merck11 9 21 16 
Total sales$214 $187 $397 $361 
Cost of sales (1)
61 61 120 123 
Selling, general and administrative29 26 58 59 
Research and development20 28 43 55 
($ in millions)June 30, 2025December 31, 2024
Receivables from Bayer included in Other current assets
$173 $160 
Payables to Bayer included in Accrued and other current liabilities
88 82 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2025202420252024
Net sales of Lagevrio recorded by Merck
$83 $110 $185 $460 
Cost of sales (1)
44 96 97 287 
Selling, general and administrative
14 16 28 32 
Research and development
6 7 14 2 
($ in millions)June 30, 2025December 31, 2024
Payables to Ridgeback included in Accrued and other current liabilities (2)
$31 $68 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2025202420252024
Selling, general and administrative $4 $14 $13 $16 
Research and development
193 65 321 133 
($ in millions)June 30, 2025December 31, 2024
Receivables from Daiichi Sankyo included in Other current assets
$21 $8 
Payables to Daiichi Sankyo included in Accrued and other current liabilities (1)
850 817 
(1) Includes accrued continuation payment.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
($ in millions)2025202420252024
Selling, general and administrative $6 $4 $12 $6 
Research and development
90 93 176 162 
($ in millions)June 30, 2025December 31, 2024
Payables to Moderna included in Accrued and other current liabilities
$22 $57